Method for quantitation of low-abundance nerve growth factor mRNA expression in human nervous tissue using competitive reverse transcription polymerase chain reaction

DNA and Cell Biology

Volumn 15, Issue 5, 1996, Pages 415-422

  Amand, Danielle S T ^a  

^a MCMASTER UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

MESSENGER RNA; NERVE GROWTH FACTOR;

ARTICLE; CELL SURVIVAL; GENE EXPRESSION; HUMAN; HUMAN TISSUE; NERVE GROWTH; NERVE INJURY; NEUROLOGIC DISEASE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; RNA ANALYSIS;

EID: 0029930825     PISSN: 10445498     EISSN: None     Source Type: Journal    
DOI: 10.1089/dna.1996.15.415     Document Type: Article

References (4)

1. ARCARI, P., MARTINELLI, R., and SALVATORE, F. (1984). The complete sequence of a full length cDNA for human liver glyceraldehyde-3-phosphate dehydrogenase: Evidence for multiple mRNA species. Nucleic Acids Res. 12, 9179-9189.
2. BERTRAND, P., ROGER, O., HOULGATTE, R., JAVOY-AGID, R., BRANDEL, J.-P., DOBLE, A., and BLANCHARD, J.-C. (1992). Measurement of nerve growth factor-like immunoreactivity in hu-man brain using an anti-mouse-NGF enzyme immunoassay. Neurochem. Int. 20, 215-218.
3. CHELLY, H., KAPLAN, J.C., GAUTRON, S., and KAHN, A. (1988). Transcription of the dystrophin gene in human muscle and non-muscle tissues. Nature 333, 858-860.
4. EIDE, F.F., LOWENSTEIN, D.H., and REICHARDT, L.F. (1993). Neurotrophins and their receptors-current concepts and implications for neurologic disease. Exp. Neurol. 121, 200-214.